RT Journal Article
SR Electronic
T1 Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian Multiple Sclerosis patients, a follow-up study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.05.19.22275317
DO 10.1101/2022.05.19.22275317
A1 Maria Laura Idda
A1 Maristella Pitzalis
A1 Valeria Lodde
A1 Annalisa Loizedda
A1 Jessica Frau
A1 Monia Lobina
A1 Magdalena Zoledziewska
A1 Francesca Virdis
A1 Giuseppe Delogu
A1 Maria Giuseppina Marini
A1 Maura Mingoia
A1 Marco Masala
A1 Lorena Lorefice
A1 Marzia Fronza
A1 Daniele Carmagnini
A1 Elisa Carta
A1 Silvy Pilotto
A1 Paolo Castiglia
A1 Paola Chessa
A1 Sergio Uzzau
A1 Gabriele Farina
A1 Paolo Solla
A1 Maristella Steri
A1 Marcella Devoto
A1 Edoardo Fiorillo
A1 Matteo Floris
A1 Roberto Ignazio Zarbo
A1 Eleonora Cocco
A1 Francesco Cucca
YR 2022
UL http://medrxiv.org/content/early/2022/05/20/2022.05.19.22275317.abstract
AB Monitoring immune responses to SARS-CoV-2 vaccination and its clinical efficacy over time in Multiple Sclerosis (MS) patients treated with disease-modifying therapies (DMTs) help to establish the optimal strategies to ensure adequate COVID-19 protection without compromising disease control offered by DMTs. Following our previous observations of the humoral response one month after two doses of BNT162b2 vaccine (T1) in MS patients differently treated, here we present a cross-sectional and longitudinal follow-up analysis six months following vaccination (T2, n=662) and a month following the first booster (T3, n=185). Consistent with results at T1, humoral responses were decreased in MS patients treated with fingolimod and anti-CD20 therapies compared with untreated patients also at the time points considered here (T2 and T3). Interestingly, a strong upregulation one month after the booster was observed in patients under every DMTs analyzed, including those treated with fingolimod and anti-CD20 therapies. And although patients taking these latter therapies had a higher rate of COVID-19 infection five months after the first booster, only mild symptoms that did not require hospitalization were reported for all the DMTs analyzed here. Based on these findings we anticipate that additional vaccine booster shots will likely further improve immune responses and COVID-19 protection in MS patients treated with any DMT.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by FISMAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of TS Sardegna gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors(MS)Multiple sclerosis(DMTs)disease-modifying therapies(SARS-CoV-2)severe acute respiratory syndrome coronavirus type-2(COVID-19)Coronavirus disease 2019(Ab)Antibody(S)Spike(N)Nucleocapsid